Results 31 to 40 of about 162,494 (358)

High clearance of (S)‐warfarin in a warfarin‐resistant subject. [PDF]

British Journal of Clinical Pharmacology, 1993
A 30 year old black male required a 60 mg daily dose of warfarin to elicit a therapeutic anticoagulant response (normal warfarin dose 2.5‐ 10 mg day‐1; maximum 15 mg day‐1). Hereditary warfarin resistance was suspected after compliance, diet, concurrent medication and any gastrointestinal disorder were eliminated as contributory causes. The disposition
AA Trowbridge, MW Modi, B. Woodruff, Peter J. Wedlund, HO Hallak, GL Lewis, IH Patel   +6 more
openaire   +3 more sources

Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]

, 2015
© Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A, Inoue, Nobutaka, Iwata, Sachiyo, Otsui, Kazunori, Ozawa, Toru, Suzuki, Atsushi, Takei, Asumi, Yamamoto, Junichiro, Yoshioka, Takayuki   +8 more
core   +2 more sources

Warfarin Pharmacogenetics [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
Significant interest in the pharmacogenetics of warfarin therapy has been triggered with the recent package insert update that highlights the potential role of pharmacogenetics in improving the safety and effectiveness of warfarin. We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the ...
Nita A, Limdi, David L, Veenstra
openaire   +2 more sources

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]

, 2012
Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Bohmann, Ferdinand, Förch, Christian, Lindhoff-Last, Edelgard, Mirceska, Ana, Pfeilschifter, Josef Martin (Prof. Dr.), Pfeilschifter, Waltraud, Steinmetz, Helmuth   +6 more
core   +3 more sources

Spontaneous abdominal hemorrhage due to warfarin treatment

CHRISMED Journal of Health and Research, 2016
Warfarin is an anticoagulant used in the prevention of thromboembolism. Common clinical indications for warfarin use are atrial fibrillation, artificial heart valves, deep venous thrombosis. Common side effect of warfarin is hemorrhage.
Mustafa Volkan Demir, Tuba Öztürk Demir, Selcuk Yaylaci, Ahmet Bilal Genc   +3 more
doaj   +1 more source

Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) [PDF]

, 2011
<p>Background: Venous thromboembolic events (VTE), including deep venous thrombosis and pulmonary embolism, are common in older age. It has been suggested that statins might reduce the risk of VTE however positive results from studies of middle ...
A Gaw, A Squizzato, A Squizzato, AD Blann, AG Holst, Allan Gaw, AM Wallace, Ann Rumley, Anton JM de Craen, AW Tsai, CC Yang, CJ Doggen, CJ Packard, D Grady, David J Stott, Dilys J Freeman, DJ Stott, E Ann Brown, Edward S Tobias, FR Rosendaal, FR Rosendaal, GD Lowe, Gordon DO Lowe, HT Sorensen, I Ford, Ian A Greer, Ian Ford, J Shepherd, J Shepherd, J Wouter Jukema, JG Ray, K Lacut, KA Darvall, KI Paraskevas, L Smeeth, M Cushman, Marijke Frölich, Michele Robertson, N Sattar, Naveed Sattar, P Eline Slagboom, P Poredos, RJ Glynn, RJ Glynn   +43 more
core   +4 more sources

Warfarin Sodium Stability in Oral Formulations

Molecules, 2021
Warfarin sodium is a low-dose pharmaceutical blood thinner that exists in two forms: the clathrate form and the amorphous form. In commercially available warfarin sodium oral suspension, the active pharmaceutical ingredient (API) is added in the ...
Evangelia Dimitrokalli, Stefani Fertaki, Michail Lykouras, Petros Kokkinos, Malvina Orkoula, Christos Kontoyannis   +5 more
doaj   +1 more source

Large-scale structure of brown rat (Rattus norvegicus) populations in England: effects on rodenticide resistance [PDF]

, 2015
The brown rat (Rattus norvegicus) is a relatively recent (
Adams, Sally, Haniza, Mohd Z.H., Jones, Eleanor P., Lambert, Mark S., MacNicoll, Alan, Mallon, Eamonn B., Smith, Robert H.   +6 more
core   +2 more sources

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P, Camm, AJ, Dabrowski, E, Fitzmaurice, DA, Fox, KAA, GARFIELD-AF Investigators, Gersh, BJ, Gibbs, L, Goldhaber, SZ, Goto, S, Haas, S, Kakkar, AK, Luo, K, Misselwitz, F, Pieper, KS, Turpie, AGG, Velentgas, P, Verheugt, FWA   +17 more
core   +2 more sources

Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin

Scientific Reports
Warfarin remains the most prescribed oral anticoagulant of choice in atrial fibrillation (AF) patient in resource-limited settings. Despite evidence linking Time in Therapeutic Range (TTR) to patient outcomes, its use in clinical practice is not ...
Paisit Kosum, Noppachai Siranart, Kunathip Nissaipan, Wattakorn Laohapiboolrattana, Walit Sowalertrat, Kanittha Triamamornwooth, Rawiwan Arunphan, Apiradee Sriyom, Voravut Rungpradubvong   +8 more
doaj   +1 more source